{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:28:44Z","timestamp":1761546524918,"version":"build-2065373602"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In ovarian cancer, the correct selection of patients for cytoreductive surgery is of great importance. The aim of this study was to evaluate the diagnostic performance of the Fagotti score assessed on preoperative diffusion-weighted magnetic resonance imaging (DW-MRI) for predicting tumor resectability in patients with ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with ovarian cancer who underwent surgical treatment between 2014 and 2022 at University Hospital Bern, Switzerland. All patients had a preoperative MRI performed. The surgical and MRI Fagotti scores were assessed retrospectively, and follow-up data were available through standardized databases and follow-up controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 52 imaging studies in 50 patients met the inclusion criteria. The majority of the patients presented with primary diagnosis (73.1%), serous histological subtype (75.0%), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (76.9%). The mean surgical Fagotti score was 3.4 (\u00b13.24), while the mean MRI Fagotti score was 2.8 (\u00b12.92). Consistency between the surgical and MRI assessments was 94.2% for stomach infiltration, 80.8% for superficial liver metastasis, and 80.8% for peritoneal, 80.8% for mesenteric, 78.8% for small bowel, 75.0% for omental, and 65.4% for diaphragmatic involvement. An MRI Fagotti score of &amp;lt;8 predicted a no residual disease (R0) resection with a sensitivity of 97.4%, a positive predictive value of 86.0%, and a negative predictive value of 83.3%. Patients with an MRI Fagotti score of &amp;lt;6 showed a significantly longer recurrence-free survival (log-rank,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.020) and overall survival (log-rank,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.043) compared to patients with an MRI Fagotti score of 6 or higher.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>According to the study results, the assessment of the Fagotti score on preoperative imaging with DW-MRI is feasible and useful in predicting tumor resectability in patients with ovarian cancer. Furthermore, an MRI Fagotti score higher than 6 is associated with worse oncological outcomes. However, further studies on a larger patient population are needed to confirm our results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1680992","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:21:33Z","timestamp":1761546093000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance of a radiological Fagotti score assessed on diffusion-weighted magnetic resonance imaging for predicting tumor resectability in ovarian cancer patients: a feasibility study"],"prefix":"10.3389","volume":"15","author":[{"given":"Franziska","family":"Siegenthaler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Zurbriggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Wyss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Imboden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flurina","family":"Saner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Wampfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucine","family":"Christe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"Solass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seline","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Christe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes T.","family":"Heverhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena C.","family":"Obmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2017.06.010","article-title":"Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer","volume":"83","author":"Michielsen","year":"2017","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004592","article-title":"Predicting resectable disease in relapsed epithelial ovarian cancer by using whole-body diffusion-weighted MRI","volume":"33","author":"Dumont","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108696","DOI":"10.1016\/j.ejrad.2019.108696","article-title":"Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer: Diagnostic performance in correlation with surgical findings","volume":"121","author":"Garcia Prado","year":"2019","journal-title":"Eur J Radiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.08.1753","article-title":"Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings\u2014A feasibility study","volume":"193","author":"Low","year":"2009","journal-title":"Am J Roentgenol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD009786","DOI":"10.1002\/14651858.CD009786.pub3","article-title":"Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer","volume":"2019","author":"Van De Vrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1471-2407-9-171","article-title":"Neoadjuvant chemotherapy or primary surgery for stage III\/IV ovarian cancer: contribution of diagnostic laparoscopy","volume":"9","author":"Brun","year":"2009","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"A73","DOI":"10.1136\/ijgc-2022-ESGO.161","article-title":"2022-RA-776-ESGO Validity of whole body MRI in the preoperative assessment of ovarian cancer: systematic review and meta-analysis","volume":"32","author":"Manzour","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO)","volume":"115","author":"Du Bois","year":"2009","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05874-y","article-title":"Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer","volume":"303","author":"Angeles","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-06887-6","article-title":"Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma","volume":"30","author":"Lee","year":"2020","journal-title":"Eur Radiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"108786","DOI":"10.1016\/j.ejrad.2019.108786","article-title":"Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery","volume":"123","author":"Rizzo","year":"2020","journal-title":"A Sing-Centr Stud Eur J Radiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s43055-020-00213-2","article-title":"The Role of Diffusion Weighted Imaging in suspected cases of ovarian cancer","volume":"51","author":"Ali","year":"2020","journal-title":"Egy J Radiol Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1038\/s41598-024-62568-0","article-title":"First external validity study of the Fagotti score in ovarian cancer","volume":"14","author":"Aida","year":"2024","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-013-2837-7","article-title":"Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma","volume":"23","author":"Espada","year":"2013","journal-title":"Eur Radiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.28418","article-title":"Diffusion-weighted magnetic resonance imaging and morphological characteristics evaluation for outcome prediction of primary debulking surgery for advanced high-grade serous ovarian carcinoma","volume":"57","author":"Li","year":"2023","journal-title":"J Magn Reson Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2019.03.007","article-title":"MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients","volume":"114","author":"Engbersen","year":"2019","journal-title":"Eur J Radiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2021.0706","article-title":"Association between high diffusion-weighted imaging-derived functional tumor burden of peritoneal carcinomatosis and overall survival in patients with advanced ovarian carcinoma","volume":"23","author":"An","year":"2022","journal-title":"Kor J Radiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004540","article-title":"Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer","volume":"33","author":"Saner","year":"2023","journal-title":"Int J Gynecol Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1680992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:21:33Z","timestamp":1761546093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1680992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1680992"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1680992","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"article-number":"1680992"}}